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Abstract
Background: Although prostate cancer is the most common cancer among veterans receiving care in the Veterans
Health Administration (VA), more needs to be done to understand and improve survivorship care for this large
population. This study, funded by VA Health Services Research & Development (HSR&D), seeks to address the need
to improve patient-centered survivorship care for veterans with prostate cancer.
Methods/Design: This is a two-armed randomized controlled trial (RCT) with a target enrollment of up to 325 prostate
cancer survivors per study arm (total anticipated n = 600). Patients will be recruited from four VA sites. Patient eligibility
criteria include age range of 40–80 years, one to ten years post-treatment, and currently experiencing prostate cancer
symptom burden. We will compare the “Building Your New Normal” program, a personally-tailored automated telephone
symptom management intervention for improving symptom self-management to usual care enhanced with a non-
tailored newsletter about symptom management. Primary outcomes include changes in symptom burden, bother, and
health services utilization at five and 12 months after enrollment. Secondary outcomes include long-term psychosocial
outcomes (e.g. subjective health, perceived cancer control). We will use multivariable regression analysis to evaluate the
impact of the intervention on primary and secondary outcomes. We will conduct a process evaluation to understand the
effective intervention components and explore possibilities for broader implementation and dissemination.
Discussion: Our central hypothesis is that intervention group participants will have improved and more confident
symptom self-management and prostate cancer quality of life following the intervention and that these outcomes will
translate to more efficient use of health services. The study results will provide much needed information about how to
optimize the quality of care, and life, of veteran prostate cancer survivors.
Trial registration: ClinicalTrials.gov ID NCT01900561; Registered on 22 July 2013.
Keywords: Prostatic neoplasms, Veterans, Self-care, Quality of life, Self-management, Survivorship, Health services
Background
Prostate cancer (PC) is the most commonly diagnosed
cancer in US veterans [1]. Over 12,000 veterans will be
diagnosed with PC in 2016 to join more than 150,000
veteran PC survivors in the Veterans Health Administra-
tion (VA). Because the majority of these veterans will live
with the disease and its treatment side effects for many
years, care during survivorship is an important priority for
the VA. Nevertheless, there has been little systematic ef-
fort to understand the extent of veteran PC survivors’
symptom burden or how their symptom burden affects
quality of life (QOL) and subsequent utilization of health
services during survivorship. This gap in knowledge was
highlighted in a recent review that recommended further
efforts were needed to improve symptom burden in can-
cer survivors more broadly and understand relationships
between symptom burden and service utilization [2].
There are three usual approaches to PC treatment in-
cluding surgery (i.e. radical prostatectomy), radiation
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therapy (i.e. brachytherapy or external “beam” radiation),
and observation (i.e. watchful waiting or active surveil-
lance) [3, 4]. While some men choose observation initially,
most eventually undergo some form of surgical, radiation,
or hormonal treatment [5]. Each treatment can have
distinct long-term side effects and many men experience
ongoing problems with urination, sexual, hormonal (e.g.
fatigue, depression), and bowel function (e.g. diarrhea and
fecal incontinence) far beyond that experienced by age-
matched controls [5–16].
Many PC survivor studies from the general population
demonstrate that such treatment-related sequelae signifi-
cantly reduce disease-specific QOL (PC-QOL) for years
following treatment [6, 8, 9, 17–22]. Studies also show
the persistence of clinically significant PC treatment-
related adverse effects well into survivorship and even
up to ten years after diagnosis (Fig. 1) [14, 23–25].
Furthermore, there are important psychosocial conse-
quences of treatment that can extend into survivorship,
including worse perceptions of subjective health and can-
cer control (including worry about recurrence and confi-
dence in one’s ability to deal with the cancer) [26–28].
Not surprisingly, PC symptoms worsen QOL and may
lead to inefficient use of healthcare services (e.g. overuse
of primary care for treatment complications such as urin-
ary incontinence). The long-term persistence of PC symp-
toms is particularly unfortunate since many symptoms
can be ameliorated or even eliminated through self-
management or clinical intervention [29–63].
While the data documenting symptom burden in the
general population of PC survivors is extensive, there
has been no large-scale study of symptom burden in vet-
eran survivors. Moreover, there have been no efforts to
identify those survivors for whom better symptom self-
management would translate into measurable improve-
ments in QOL and more efficient use of healthcare
services. Our pilot findings demonstrated that veteran
PC survivors need and want assistance reducing their
symptom burden and improving their disease-specific
QOL. Yet, a system for patient-centered symptom as-
sessment, self-management support, and connection to
the appropriate healthcare providers for these survivors
was lacking. Findings from our pilot studies also clearly
support the feasibility of our proposed approach to com-
bining automated symptom assessment with a tailored
newsletter as a strategy for supporting symptom man-
agement among veteran PC survivors.
To address this gap in PC survivorship care in the VA,
our team has embarked on a large randomized con-
trolled trial (RCT) of a self-management support inter-
vention. As we discuss below, the proposed project is
based on pilot work, but will extend the intervention to
survivors who are further from initial treatment. Using
automated voice response (also called interactive voice
response or IVR), we will assess ongoing symptoms
(urinary, bowel, sexual, emotional, and general) in PC
survivors and deliver self-management guidance to them
in a series of tailored newsletters. We termed this inter-
vention the “Building Your New Normal” (BNN) program.
This low-cost tailored intervention will be compared with
a non-tailored newsletter about self-management for a
control group (BNN-control). We will evaluate the impact
of the BNN intervention on primary outcomes of symp-
tom burden and bother using the Expanded Prostate
Cancer Index Composite (EPIC) measure, and secondary
outcomes of self-management implementation, confi-
dence in self-management, cancer control and outlook,
self-efficacy in patient-physician interactions, and coping
through conducting follow up surveys with participants at
five and 12 months post enrollment. We will also assess
use of PC-related health services through an audit of par-
ticipants’ self-reported use and administrative data. Lastly,
we will conduct a process evaluation to evaluate the BNN
intervention’s full impact and prospects for broader dis-
semination and implementation.
Conceptual framework
The conceptual framework for our intervention is the
model of “Self-Management and Recovery following
Cancer Treatment” proposed by Foster and Fenion
(Fig. 2) [64], which describes the potential for self-
management to have a positive impact on patient-
reported outcomes for cancer survivors. The theoretical
foundations for this framework are from social cognitive
theory (e.g. the role of self-efficacy in health and well-
being) and the transactional model of stress and coping
(e.g. coping appraisal) [65, 66]. The framework is sup-
ported by a robust literature identifying the importance
of self-care for chronic disease and prior studies demon-
strating improved health outcomes and QOL among
Fig. 1 Symptom burden in PC survivors by treatment type
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cancer patients as mediated through greater self-efficacy.
In this framework, the diagnosis of cancer, cancer
treatment, and treatment-related consequences are seen
as decreasing a person’s sense of health and wellbeing.
This disruption is followed by appraisal of the situation
(i.e. coping appraisal) and appraisal of cancer-related
self-efficacy to manage the situation. The person’s coping
appraisal and self-efficacy then influence the type of self-
management strategies that are used. The type of self-
management strategies chosen influence whether the
problem is managed effectively (i.e. a reduction in symp-
toms or perceived burden) and thus the degree of recovery
of subjective health and potential improvement in cancer
outlook [67]. The effects of cancer, coping appraisal, and
self-efficacy are in turn influenced by pre-existing factors
(e.g. age, gender, social roles, co-morbidities), personal
factors (e.g. personality factors, mood states, general self-
efficacy), and environmental factors (e.g. external support,
healthcare services).
Within this framework, our proposed intervention will
use a patient empowerment approach to specifically im-
prove coping appraisal, self-efficacy for interacting with
clinicians, and self-management strategies thereby poten-
tially improving subjective health and cancer outlook. Em-
powerment is a patient-centered, collaborative approach
that is tailored to match the patient’s health experience
[68, 69]. Key elements of the empowerment-based ap-
proach include clarification of issues from the patient’s
perspective (e.g. assessment of subjective “bother” as well
as objective symptoms burden) and patient-directed goal
setting and action planning (e.g. patient selection of prior-
ity symptom areas and self-management strategies). The
intervention we propose to evaluate will also incorporate
elements of cognitive behavioral therapy (CBT)-based
self-management. CBT strategies are particularly relevant
because they are specifically designed to simultaneously
target reductions in symptoms as well as associated dis-
ability, emotional distress, and QOL [70]. During CBT,
multiple skills are taught that address both cognitive
processes (e.g. addressing overgeneralization, develop-
ing coping self-statements) and adoption of specific be-
havioral strategies (e.g. modified fluid intake, intentional
partner communication). The success of CBT-based self-
management interventions inside and outside the VA to
reduce symptoms and improve function in patients with
chronic conditions [71–73] lends support to our plan to
apply these strategies to enhance self-management of
post-treatment symptoms, coping, confidence, and cancer
outlook among PC survivors.
Though there have been no comprehensive self-
management interventions directed to help survivors re-
duce the negative consequences of PC treatment in every-
day life, research suggests such interventions are likely to
have a positive impact [74]. As shown in Table 1, each do-
main of PC treatment-related symptoms has correspond-
ing self-management approaches with varying degrees of
evidence. For example, urinary symptoms can be self-
managed through a variety of approaches including
emptying the bladder at regular intervals before it gets too
full and pelvic floor (i.e. Kegel) exercises to help decrease
urinary leakage. In fact, a RCT demonstrated a 50% de-
crease in incontinence episodes among PC survivors using
pelvic floor muscle training and bladder control strategies
[75]. A recent systematic review concluded that exercise
improves incontinence, fatigue, body constitution, and
QOL after treatment for PC [74]. Exercise among PC
survivors is also associated with decreased mortality
[76]. For sexual functioning after PC treatment, min-
imizing tobacco and excessive alcohol use, and com-
municating with partners about feelings and sex, are
self-management strategies for improving sexual rela-
tionships and intimacy [77]. Avoiding spicy, greasy
foods, coffee and alcohol, and staying well-hydrated
may help limit the adverse bowel effects of radiation
(i.e. radiation proctitis) among PC survivors [78].
However, there is no current systematic mechanism
Fig. 2 Conceptual model for self-management and recovery following cancer treatment
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to share these strategies with veterans, despite their
desire for knowledge of these approaches reported in
our pilot survey.
Specific aims
For these reasons, we aim to evaluate the ability of this
intervention to improve key outcomes for veteran PC
survivors. Based on our conceptual framework, the over-
arching goal of this study is to determine whether an
intervention using highly personalized automated tele-
phone monitoring and self-management support calls
paired with tailored print materials can effectively im-
prove outcomes for veteran PC survivors. The study
aims are as follows:
Aim 1: To conduct a randomized controlled trial among PC
survivors with high symptom burden comparing the impact
of a personalized intervention for improving symptoms and
symptom self-management to non-personalized
information
We hypothesize that relative to control participants, vet-
erans in the BNN intervention group will: (1) have
higher confidence about symptom self-management; and
(2) report lower symptom burden and better disease-
specific QOL at five and 12 months post enrollment.
We further hypothesize that at the 12-month assessment
point, the intervention group will have higher scores on
two key psychosocial indicators (subjective health and
perceived cancer outlook) than the control group.
Aim 2: To determine the intervention’s impact on the use of
primary and specialty VA services
We hypothesize that relative to control participants,
veterans in the BNN intervention group will have a
higher rate of symptom-specific service use that is
consistent with published expert and evidence-based
recommendations for PC survivorship care 12 months
after enrollment [79].
Methods/Design
This is a two-armed RCT with an enrollment target of up
to 325 PC survivors per arm (total anticipated n = 600).
The intervention arm will receive the BNN intervention
for improving symptom self-management. The control
arm will receive enhanced usual care, consisting of one
non-tailored newsletter describing self-management ap-
proaches in general. The Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) Checklist is
presented as Additional file 1.
Setting
This study is being conducted in four sites: the VA Ann
Arbor Healthcare System (VAAAHS), the Louis Stokes
Cleveland VA Medical Center (LSCVAMC), the VA
Pittsburgh Healthcare System (VAPHS), and the St.
Louis VA Medical Center (SLVAMC). Based on initial
assessment of recruitment numbers, we added the
LSCVAMC after the study began to meet recruitment
goals. The sites offer significant numbers of potentially
eligible survivors including racial/ethnic minority vet-
erans (e.g. African Americans).
Table 1 Symptom self-management strategies for PC survivors
PC health domain





Erectile dysfunction, compromised masculinity,
poor libido, poor communication, unable to
engage in sexual activity
Diarrhea, fecal incontinence, increased





























Making time for and enhancing intimacy [41]
Creative intimacy (non-penile) [42–46]
Having an orgasm without erection/avoiding
climacturia [47–49]
Reduce alcohol and tobacco [50, 51]
Using a vacuum erection device [52–55]
(NOTE: medical strategy following self-
management approach)
Pelvic floor exercises (Kegels) [56, 57]
Diet for softer stools (fiber) [58]
Diet to avoid irritation
Proper fluid intake
Reducing painful bowel mvts
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Patient population and eligibility criteria
We will identify potential study participants using
methods successfully used in prior studies of veteran PC
survivors. Specifically, veterans who have been treated
for PC by surgery or radiation therapy (using ICD-9 and
HCPCS treatment codes) in the prior one to ten years
will be identified from the VA National Patient Care
Database and Corporate Data Warehouse data files. This
eligibility was broadened from five years to ten years to
help meet our recruitment goals. Patients treated with
androgen deprivation therapy (ADT) will be eligible. To
be eligible, patients must be aged 40–80 years and have
a working cell or landline telephone. Patients will be in-
eligible if they are undergoing treatment for a non-PC,
have dementia, or other significant mental impairment
noted in their medical record.
Potential risks and protections against them
The potential risks to patients participating in the study
are minimal, as the intervention consists of participating
in telephone assessments and receipt of tailored educa-
tion or standard education similar to that available from
other sources. Potential risks include loss of confidenti-
ality and psychological distress. The psychological risks
are related to possible coercion and potential emotions
that may arise when responding to survey questions
about health status and the challenges associated with
managing symptoms of PC treatment including sexual
health symptoms. Every effort will be made to minimize
these risks. To avoid the possibility of coercion, an opt-
out telephone number is provided and potential partici-
pants are told they are under no obligation to participate
(i.e. it is a voluntary study) and that their care will not
be affected by their decision to participate or not. Partic-
ipants will be instructed to skip any survey question they
do not wish to answer and are told that they may with-
draw from the study at any time without penalty. To
minimize the risk of loss of confidentiality, all data will
be stored in secure locations accessible only to study
team members.
It is possible the automated system and follow-up sur-
veys may uncover certain symptoms that warrant med-
ical attention. Two such possible symptoms include
blood in stool and/or urine. If a study participant reports
blood in stool and/or urine (or other concerning symp-
toms requiring the input of a physician), study staff will
personally contact the participant via telephone to con-
firm the report. For all participants verifying current or
recent symptoms, the appropriate provider will be noti-
fied. In the event a study participant has no assigned
provider(s) at the VA appropriate for follow-up of re-
ported concerning symptoms, study staff will encourage
the participant to notify his primary care (or other) pro-
vider of the symptoms. Should the study participant ex-
press concerns or request additional information, or in
the event the participant has no assigned community-
based provider, the patient will be contacted by a study
investigator who is a physician. In the event we are un-
able to reach participants by phone, study staff will send
a letter by mail encouraging them to notify their pro-
vider of the reported symptoms.
Although we do not specifically ask about suicidal ide-
ations, we do assess degree of depression in the EPIC
measure and, as part of our tailoring for participants in-
dicating they wanted help with depression symptoms,
we included VA options to get help including talking
with their primary care clinician and VA hotlines.
Patient recruitment and consent
Patient recruitment will occur over a period of two
years. (Note: recruitment started April 2015 and is pro-
jected to be completed by April 2017.) The project data
manager reviews VA data files on a rolling basis to iden-
tify potentially eligible patients across all sites. Using the
list compiled by the data manager, the project team
sends a recruitment packet with an introductory letter
and information sheet to potential participants (Fig. 3).
The introductory letter includes a brief introduction to
the study signed by the overall PI and the local site PI,
plus a local or toll-free number to call for additional in-
formation or to request no further study-related contact
Fig. 3 Study design
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(i.e. to “opt out”). The information sheet stands in for
the informed consent document and includes a detailed
description of the study and its potential benefits and
risks. One week after the recruitment packet mailing, a
research coordinator calls those veterans who have not
declined further contact. Up to six attempts will be
made. If patients have not been reached by the sixth at-
tempt, no further contact is made.
Once a potentially eligible veteran has been reached,
the research coordinator will briefly describe the study
and ask if they would be interested in participating. Vet-
erans who decline will not be contacted further; how-
ever, reason for refusal is requested and recorded when
provided. Those who agree to participate will be asked
to complete a brief screening tool to gauge desire for
help managing symptoms in one of the four symptom
areas: urinary, sexual, bowel, and general health. This
screener asks veterans to indicate how much they would
like help with managing symptoms in any of the four
symptom areas (on a scale of 0 to 5, with 0 indicating
patient does not want any help managing symptoms and
5 indicating patient would very much like help).
Veterans scoring 1 or higher on any one symptom, as a
measure of low function or high symptom burden, will
be considered eligible to participate. Importantly, the
screener is designed so that if the veteran wants help
with a symptom—even if not really experiencing
treatment-specific problems in that area—he is able to
participate. The screener was designed to ensure that
any PC survivor had the opportunity to participate in
the study and work on a selected symptom domain of
their choice through the tailored intervention. Each pa-
tient will receive an honorarium of $10 following
randomization into one of the two arms that is sent to
them in the mail. Any veteran who sounds depressed, or
expresses depression or suicidal thoughts during the call
with the research assistant is strongly encouraged to
contact their PCP, and is given the telephone number
for the suicide hotline. If a veteran expresses being un-
happy with his care or with the VA specifically, the re-
search coordinator offers to contact patient services and
arranges a follow-up phone call to the veteran from the
patient care representative.
Patient baseline survey and randomization
The baseline survey for eligible patients is divided into
two sections. The first half is conducted by the research
coordinator immediately after screening questions and
prior to randomization for all participants. This section
verifies and collects patient demographics, confirms PC
treatment type and diagnosis date, and assesses cancer
outlook at the time of enrollment. We also administer
the Perceived Efficacy in Patient-Physician Interactions
(PEPPI) scale in this section. After completing this half
of the baseline survey, participating patients are random-
ized by the computer into the BNN-intervention or
BNN-control group. The randomization is stratified by
original treatment type (surgery, radiation, or multiple
types) to ensure there are equal proportions of patients
by these factors in both arms. The randomization proce-
dures are done via the computer console while the vet-
eran is on the telephone. There is no way for
randomization group to be determined prior to this
point, nor is there any way to change the randomization
group after it is completed.
After randomization, the second half of the baseline
survey is initiated which consists of the standardized
symptom burden questionnaire, the 26-item Expanded
PC Index Composite (EPIC) instrument used to assess PC
symptom burden and associated PC-QOL. To ensure the
administration of the EPIC is standardized across partici-
pants, the EPIC will be administered to both intervention
and control participants through the automated telephone
system. The automated system will try to reach the vet-
eran up to eight times over the course of four days follow-
ing randomization to deliver EPIC. Even if the EPIC
cannot be administered, the participant remains in the
study per the intent-to-treat approach as discussed below.
(See the “Data collection instruments” section below for
more information on the PEPPI and EPIC.)
Content and delivery of the BNN intervention
Intervention content
The BNN is a patient-centered intervention designed to
improve confidence in symptom self-management, reduce
symptom burden, and have subsequent positive impacts
on subjective health (quality of life) and cancer outlook.
The intervention is based on pilot work conducted by the
study team and includes two components: (1) the auto-
mated voice response (IVR) telephone calls to assess
symptoms and to offer participants the chance to choose a
symptom to focus on (i.e. priority symptom); and (2) the
tailored newsletter which is sent following the IVR that in-
cludes more detail about the symptom area chosen, as
well as CBT-based approaches for coping with symptoms
(see Fig. 4). Further detail regarding the delivery of the
intervention components is provided below.
Intervention delivery
Veterans randomized to the BNN intervention will receive
four automated phone calls over a three-month period:
one call at study start and then once a month for three
months. These calls will last approximately 15–25 min
and include questions about symptoms, allow the veteran
to identify a goal to work on, and help the veteran take
steps towards reaching their goal and managing their
symptoms. At the end of each call, the veteran will also
have the option of listening to an audio testimonial
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tailored on a priority symptom area. Following each call,
the veteran will receive a personalized newsletter that will
provide more details regarding their symptoms and strat-
egies to help them manage their symptoms. These recom-
mendations are largely based on the Michigan Cancer
Consortium Guidelines for the Primary Care Management
of Prostate Cancer Post-Treatment Sequelae which
include self-management, pharmacologic, medical, and
surgical management strategies across the functional do-
mains in EPIC [79]. Each newsletter will be four to eight
pages in length. Example newsletter pages are illustrated
in Fig. 4. The automated system will try to reach the
veteran up to eight times over the course of four days
(see Additional file 2: IVR call schedule). If the veteran
has not completed the call by day 3 of the call window,
study staff will make up to five or six attempts to contact
the participant to verify the phone number and preferred
call time. If the veteran has still not completed the call by
day 5 of the call window, study staff will again make up to
five or six attempts to contact the participant. Following
each month’s reminder call, study staff will have the
option to initiate additional automated calls should the
veteran be agreeable. Veterans randomized to the BNN-
control group will receive one four-page newsletter with
educational information about symptoms and symptom
management following completion of the baseline EPIC
automated call.
Follow-up assessments
Follow-up assessments will be completed by both groups
at five and 12-months post enrollment. Beginning
approximately four months following enrollment, initial
attempts will be made by the study team to contact par-
ticipants by phone to complete the five-month assess-
ment and approximately 11 months following
enrollment to complete the 12-month assessment. Up to
five or six attempts will be made to contact participants
for completion of follow-up assessments. Times to
complete the surveys will be scheduled as desired by
participants. The follow-up telephone interviews will
take approximately 25–30 min based on piloting with
the study team, with an anticipated range of 15–45 min
depending on the participant’s ability to engage in the
process. If participants are unable or unwilling to
complete the survey by telephone, or cannot be reached
by phone, a paper-and-pencil survey will be mailed to
them with a return envelope. Participants who fail to re-
turn the paper survey within one month will be sent a
second paper survey by mail. In addition, a reminder
newsletter will be sent to participants one to two
months prior to their expected 12-month follow-up.
Follow-up surveys are also divided into two parts with
the first part being administered by a research coordin-
ator and the second half (the EPIC) being administered
by the automated telephone system, again to ensure
standardization of delivery of EPIC across groups.
Data collection instruments
Outcomes for Aim 1
The primary outcomes for Aim 1 (to evaluate the effect-
iveness of the BNN intervention for improving veteran-
centered outcomes through an RCT) will be based on
participant survey responses and our conceptual model
(Fig. 2) for the anticipated impact of self-management
Fig. 4 Personally tailored newsletter example
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on these response outcomes. The primary outcomes in-
clude: (1) confidence in symptom self-management as
assessed at the five- and 12-month follow-ups; and (2)
the symptom burden experienced by veteran PC survi-
vors and associated PC-QOL, as assessed through the
EPIC at baseline, five, and 12 months (see SPIRIT Fig-
ure: Fig. 5).
Secondary outcomes for Aim 1 include longer-term
psychosocial outcomes, specifically subjective health
(assessed at 12 months) and perceived cancer control
and outlook (assessed at five and 12 months), both of
which have been shown to be impacted by PC treatment
[26–28], and, as noted earlier, both of which may be also
be improved through effectively addressing coping and
self-efficacy. We will also examine efficacy in patient–
physician interactions and appraise coping as described
below. Last, we will measure whether participants state
they implemented a self-management approach and
their overall satisfaction with the program.
Confidence in symptom self-management
To evaluate survivors’ confidence in addressing specific
symptoms, we will use a five-question instrument devel-
oped for this study based on previous unpublished pilot
work. Respondents indicate how confident they are that
they: (1) understand why they experience symptoms after
PC treatment; (2) know how to do things on their own
(i.e. self-management) to address their symptoms; (3)
know how their doctors can help with their symptoms; (4)
can discuss their specific symptoms with their healthcare
providers; and (5) feel knowledgeable about managing
symptoms at home. Response options are based on a scale
of 1–3 from “not at all” to “very confident.”
Symptom burden and QOL
We will use the EPIC instrument to assess symptom bur-
den and PC-QOL at all three time points in this study. The
EPIC has been widely used in PC survivorship research and
practice including with automated telephone assessment by
our group [6, 22, 80–82]. It is a 26-item measure that as-
sesses symptom burden in four domains: urinary symptoms
(nine items), bowel symptoms (six items), sexual symptoms
(six items), and vitality (five items) (see Additional file 3:
EPIC). Each domain has a subscale related to function and
bother which together contribute to disease specific quality
of life. These domains have good internal consistency
(Chronbach’s alpha > 0.82 for each domain) and correlate
highly with other established measures of QOL [80].
Each domain has a range of possible scores from 0 to
100, with lower scores indicating lower function in
that domain (e.g. lower sexual health function) and lower
QOL [80, 81, 83]. Thus, higher symptom burden, which
reflects both function and bother, translates into lower
EPIC scores. For purposes of this study we will consider a
score of 70 or less to indicate “clinically meaningful symp-
tom burden” for any one domain [84].
Subjective health
We will assess subjective health using three items from
the VR-12 (SF-12 for veterans), an established measure
of overall QOL that includes perceptions of one’s health
that may be impacted by PC.
Cancer control and outlook
We will assess perceived cancer control and outlook
using five items from a validated measure developed to
examine the psychosocial impact of PC [26–28]. This
measure, the Measuring Patients’ Perceptions of the
Outcomes of Treatment for Early PC instrument by
Clark et al., includes three domains related to confidence
that one’s cancer is under control, worries about recur-
rence, and appraisals of one’s coping with PC. Cancer
control will be assessed during the five- and 12-month
follow-ups using three cancer control items from the in-
strument. Cancer outlook will be assessed at all three
times points using the cancer outlook items from the
instrument.
Efficacy in patient–physician interactions
Self-efficacy in patient–physician interactions will also be
assessed at all three time points using a five-item short
form version of the Perceived Efficacy in Patient-Physician
Fig. 5 SPIRIT Figure: data collection instrument source and time of collection
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Interactions (PEPPI) [85]. The PEPPI was developed to
measure older patients’ self-efficacy in obtaining medical
information and attention to their medical concerns from
physicians.
Coping appraisal
We will assess participants’ coping during the five- and 12-
month follow-up assessments using six items from the 28-
item Brief Cope instrument. This instrument measures
emotion-focused, problem-focused, and dysfunctional cop-
ing and has been used in cancer survivors [86].
Outcomes for Aim 2
The primary outcome for Aim 2 will be use of VA health
services related to PC survivorship care at the 12-month
assessment point from enrollment. We will use the 12-
month assessment point to ensure we capture any medi-
cation or service use related to PC symptom manage-
ment that may occur after participants’ exposure to the
intervention has ended. Because there are no VA guide-
lines for appropriate management of PC survivors, we
will operationalize symptom-specific utilization consist-
ent with published expert- and evidence-based guide-
lines for PC survivorship care [87]. These guidelines are
meant to provide point-of-care recommendations for
self-management, pharmacologic, medical, and surgical
management strategies across the functional domains
addressed in our study. We will use criteria mapping to
operationalize utilization consistent with these guideline
recommendations [88]. This process has been used ex-
tensively to develop sets of quality metrics using a set of
recommendations, when evidence-based guidelines do
not exist [89]. Specifically, for each symptom indicated
by the participant at baseline, we will determine poten-
tially appropriate use of services by mapping receipt of
services at the 12-month follow-up to those outlined in
the guideline recommendations. For analysis purposes,
we will consider recommended survivorship care as
“guideline-concordant” even though the guidelines are
not fully evidence-based.
The outcomes for Aim 2 will be obtained from three
VA data sources. We will collect pharmacy data from
the VA Corporate Data Warehouse. National Patient
Care Database records will be accessed for information
including patient demographics, diagnoses, the date and
type of utilization events, location of services (study site
as well as clinic type), and the participants’ assigned pri-
mary care provider. To obtain information about device
utilization, such as a penile clamp for incontinence con-
trol, we will use the National Patient Prosthetics Data-
base from Patient Care Services. Having these records
will ensure we can collect the most accurate device
utilization. More broadly, we will use the datasets cre-
ated through Aim 2 to assess primary and/or specialty
care receipt 12 months post enrollment. To account for
services potentially received outside of the VA, we will
ask participants at both the five- and 12-month assess-
ments to report the number of times over the prior
period that they visited their VA or non-VA primary care
physician and specialist (urologist, oncologist, radiation
oncologist, or gastroenterologist). For each visit, we will
ask them to indicate whether the visit was related to
their PC symptom management.
Analysis
Assessment of intervention uptake and intent-to-treat
A key consideration in this type of study is the degree to
which those randomized to the intervention arm actively
use the automated calls and tailored newsletters. Based on
prior work, we anticipate drop-out to be small and that
most participants randomized to the BNN intervention
arm will complete at least three out of the four automated
calls [90]. Prior studies using tailored newsletters also have
shown that patient engagement is high, with one study
conducted by our collaborator showing increased fruit
and vegetable intake following delivery of tailored newslet-
ters. Nevertheless, our primary analysis will be based on
the intent-to-treat principle (ITT), [91] and will include all
participants regardless of engagement in the intervention
for both five-month and 12-month outcomes analyses.
We will make every effort to obtain both five- and 12-
month follow-up assessments of all randomized partici-
pants regardless of whether or not they completed the
intervention sessions.
Completer analysis
In addition to ITT analysis, we will also do “completer”
analysis where the completers will be defined as those
who complete at least one automated call, and who
complete the baseline and 5-month assessments. We will
do similar completer analysis for long-term outcomes
using 12-month assessments. If baseline characteristics of
completers and non-completers are found to be different,
we will also estimate the complier average causal effect
[92]. This method uses the randomization process as an
instrument to give an unbiased estimate (and standard
error) of the causal effect of the intervention among those
participants who actively participate. This approach is use-
ful when trying to isolate the effect of the intervention
itself independent of the effect of the intervention uptake
rate on the overall intervention effect.
Engagement in intervention
Non-engagement in the intervention will include not
only those with intermittent call completion, but also
those who dropped out of the study or were lost-to-
follow-up. We will compare dropout rates across inter-
vention groups and we will use logistic regression
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models to explore predictors of dropout which include
an indicator for intervention arm, key baseline charac-
teristics (e.g. baseline symptom severity or measures of
socioeconomic vulnerability), and interactions between
group assignment and participant characteristics. The
extent of missing data for baseline covariates as well as
the missing outcome values at each follow-up assess-
ment will be determined separately by study group. We
will implement various methods including sensitivity
analyses and multivariate sequential regression tech-
niques to account for missing data and study dropout.
Aim 1
Initial analyses and data verification
Baseline analysis (data verification) will include examin-
ing the distribution of all study variables to assess ex-
treme values, missing data, variances, skewness, and
type of distribution. Descriptive statistics will be used to
describe the distribution of baseline variables in the two
groups. We will use means, medians, and ranges for
continuous variables such as age and baseline symptom
scores, and we will use proportions for discrete variables.
To assess balance between groups in the distribution of
baseline characteristics, we will conduct baseline com-
parability of the two groups.
Aim 1 outcome analyses
Our primary outcomes for Aim 1 will be symptom
scores using the EPIC measure and confidence in symp-
tom self-management at five months. We will also evalu-
ate these outcomes at the 12-month assessment point,
but focus on the 5-month assessment for primary out-
come assessment as it is closer to the completion of the
intervention. We will also report by study group the per-
cent of participants who reached EPIC symptom scores
above 70 (i.e. “better symptom burden”) and better EPIC
scores at both five and 12 months. We will evaluate the
trends in symptom burden, and knowledge and informa-
tion need over time by the two study groups. Results of
these graphical analyses will be used to fine-tune the
analytic course described below. Multiple regression
analysis will be used to evaluate the primary outcomes
in two stages. The first model will include an indicator
for study group (intervention versus control) as the pri-
mary independent variable, adjusting for sites and treat-
ment type received (radiation versus surgery). The
second model will further adjust for baseline prognostic
variables (i.e. age, education, income, race, and baseline
symptom burden [EPIC score]).
The coefficient for the intervention group indicator
will be used to evaluate the impact of the personalized
automated PC symptom management program com-
pared to non-tailored, standard information received by
the control participants. We will repeat the analysis
using each of the four symptom domains for EPIC. We
will use the same analytic approach to evaluate confi-
dence in symptom self-management and other second-
ary Aim 1 outcomes. We hypothesize that for all Aim 1
outcomes, intervention group survivors will have better
scores at both five- and 12-month assessments relative
to those in the control group (i.e. less symptom burden,
higher confidence in symptom self-management, and
better cancer outlook).
We will also assess the trajectory of symptoms over
time. This will be done using a linear mixed-effects
model with random effects for each subject, an indicator
for intervention group, indicators of follow-up waves
(five months and 12 months with baseline as reference)
and interactions of follow-up times by intervention
group to model potential changes in the intervention
effect on symptoms soon (at five months) versus long
(at 12 months) after the intervention is discontinued.
If the contrast between five- and 12-month interaction is
not significant, we will combine the post-enrollment times
and estimate the time-averaged difference in outcomes be-
tween the two study groups. Analyses of other outcomes,
such as self-management implementation and confidence,
will also be assessed for the trajectory over time.
Aim 1 sample size and statistical power
We will use the minimal, clinically important difference in
EPIC score for each of the four domains [84] to determine
clinically meaningful differences in the between-group
means for symptom scores by each domain. To detect a
0.33 standard deviation (SD) difference in symptom scores
between participants receiving the automated PC symptom
support versus standard information at 12 months with
90% power, we need 394 participants (197 per group),
based on a regression analysis adjusting for baseline values
with an α of 0.0125 with 0.5 as an assumed correlation be-
tween baseline and follow-up symptom scores. Note that
the primary endpoint is five months, but we powered con-
servatively to detect a difference at 12 months and that the
α value was chosen conservatively to detect symptom score
difference in any of the four domains. The power will be
higher to detect a larger than 0.33 SD between-group differ-
ence in symptom scores and also to detect the same differ-
ence with higher correlation than 0.5 between baseline and
follow-up symptom values. Assuming conservatively 15%
attrition at each assessment time, we propose to enroll 550
participants in total with an anticipated 397 participants to
complete assessments at 12 months. The number of eligible
PC patients at each site is sufficient for recruitment. For
interval scale outcome measures, such as confidence in
symptom self-management, the proposed sample size
should give adequate power to detect at least 0.33 SD dif-
ferences between groups.
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Aim 2
For Aim 2, we hypothesize that 12 months after enroll-
ment, veterans in the automated PC symptom management
intervention will have higher rates of use for PC survivor-
ship services that are consistent with guideline recommen-
dations than control participants. As described above, the
primary outcome for Aim 2 will be use of symptom-
specific guideline-concordant care assessed at 12 months.
Using our global measure of use of any symptom-specific
guideline-concordant care (yes/no), we will evaluate differ-
ences between intervention conditions using a logistic re-
gression model including all participants and controlling
for a priori baseline prognostic variables. We will then
conduct additional logistic regression analysis within sub-
groups of patients with various symptom patterns at base-
line. For these models, the primary outcome will be use of
guideline-concordant care for a specific symptom (yes/no).
We will control for veteran demographics (including age,
race, education, and income), study site, type of treatment
received (i.e. radiation, surgery, ADT). We will also explore
the total amount of guideline-concordant services received
in regression models appropriate for skewed count data
(e.g. poisson or negative binomial models).
Process evaluation
In addition to evaluating effectiveness of the interven-
tion using standard RCT methods, rigorous and compre-
hensive process evaluation is essential to evaluate the
full impact and prospects for broader dissemination and
implementation [93]. We will conduct semi-structured
qualitative interviews with up to 40 intervention partici-
pants (ten per site) and up to 40 stakeholders (four PCPs
and four specialists at each site, plus interviews of VA
stakeholders at the regional and national levels) to id-
entify contextual factors that influence adoption and
implementation [94] and to assess the patient-related
factors impacting the intervention’s reach, engagement,
satisfaction, and effectiveness [80, 95].
Discussion
Rationale for undergoing the trial
To our knowledge, the results of this RCT will be the
first to compare easily scaled, tailored interventions for
veteran PC survivors to standard interventions providing
only basic non-tailored information on symptom man-
agement. Our pilot work provided compelling motiv-
ation for research to assist survivors with innovative
services designed to increase access to self-management
and medical management of their treatment-related
symptoms. In addition, little is known about the associ-
ation between PC-related symptom burden and service
use in the VA, but our pilot study found that half of re-
spondents did not know when to seek primary or spe-
cialty care to address their symptom(s). Further work is
needed to understand how veterans’ symptom burden
drives their use of health services and whether there is
over- or under-use of care (or both). Moreover, VA leader-
ship needs information about whether a symptom self-
management intervention can improve appropriate ser-
vice use for cancer survivors. Such information can
provide better direction for survivors and their clini-
cians regarding how to optimize survivorship care both
inside and outside of VA.
Dissemination
Upon completion of the study and analysis of data, we
plan to work with the primary care teams at each site in
disseminating the study results. This will include pre-
senting results to the local urology and primary care de-
partments and nationally at research and operational
meetings. Following completion of the 12-month assess-
ment, participating patients will receive a newsletter
containing some preliminary study results.
Future directions
Should our analysis show the intervention is effective,
we will work with the VA Office of Specialty Care Ser-
vices to determine appropriate methods for broader dis-
semination. We will also plan to design and test an
intervention for use in other healthcare delivery systems.
Trial status
Patient recruitment started in April 2015 and will continue
through the end of April 2017. As of February 23, 2017, the
study has recruited 556 participants (target: 553–650).
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